IndraLab
Statements
reach
"Using the combination of P5091 (an inhibitor of USP7) and PD-1 monoclonal antibody, researchers were able to demonstrate a synergistic anti-tumor impact, which bodes well for the future of lung cancer therapy.96 Furthermore, in gastric cancer, the amount of PD-L1 is favorably linked with the level of USP7."